Siv Jonsson

Dr. Siv Jonsson


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2016 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
CWCathelijne van der Wouden
Cathelijne van der Wouden
ACA Cambon‐Thomsen
A Cambon‐Thomsen
Erika CecchinErika Cecchin
Erika Cecchin
KCKc Cheung
Kc Cheung
CDCristina Lucía Dávila-Fajardo
Cristina Lucía Dávila-Fajardo
Evangelia Eirini TsermpiniEvangelia Eirini Tsermpini
Evangelia Eirini Tsermpini

26 June 2009 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SBSven Björkman
Sven Björkman
AFAnna Folkesson
Anna Folkesson
SJSiv Jonsson
Siv Jonsson

1 February 2008 in Pharmacogenetics and Genomics
Verified
Journal Article
Closed access
SFSamuel Fanta
Samuel Fanta
MNMikko Niemi
Mikko Niemi
SJSiv Jonsson
Siv Jonsson
MKMats O. Karlsson
Mats O. Karlsson
CHChrister Holmberg
Christer Holmberg
JBJanne T. Backman
Janne T. Backman
Objective To evaluate whether variations in the ABCB1, ABCC2, SLCO1B1, CYP3A4, CYP3A5, or NR1I2 genes are associated with the pharmacokinetics of cyclosporine in pediatric renal transplant candidates, and whether the effects of these variants are related to age. Methods A total of 104 pediatric patients (aged 0.36–16.3 years) were genotyped for 17 putatively functionally significant sequence variations in the ABCB1, SLCO1B1, ABCC2, CYP3A4, CYP3A5, and NR1I2 genes. The patients had undergone a pharmacokinetic study with intravenous and oral ciclosporine (INN, cyclosporin) before renal transplantation. Results In the whole population, the mean±SD cyclosporine oral bioavailability was 0.38±0.09, volume of distribution was 2.3±0.54 l/kg, and systemic clearance normalized by allometric body weight was 0.88±0.16 l/h/kg3/4. The prehepatic extraction ratio was 0.51±0.13, and the hepatic extraction ratio was 0.24±0.04, the former explaining 95% of the variability in oral bioavailability (PT variant and the related haplotype c.1199G-c.1236C-c.2677G-c.3435C (P<0.05). The estimated oral dose requirement and clearance of cyclosporine remained largely unexplained by the genetic variations. Conclusions Although these data suggest an age-related effect of ABCB1 polymorphism on oral bioavailability, further studies are required on the predictive value of genotyping for individualization of cyclosporine dosing in children.

14 February 2019 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
JAJoão A. Abrantes
João A. Abrantes
SJSiv Jonsson
Siv Jonsson
MKMats O. Karlsson
Mats O. Karlsson
ENElisabet Nielsen
Elisabet Nielsen
Aims: This study aims to assess approaches to handle interoccasion variability (IOV) in a model‐based therapeutic drug monitoring (TDM) context, using a population pharmacokinetic model of coagulation factor VIII as example.Methods: We assessed 5 model‐based TDM approaches: empirical Bayes estimates (EBEs) from a model including IOV, with individualized doses calculated based on individual parameters either (i) including or (ii) excluding variability related to IOV; and EBEs from a model excluding IOV by (iii) setting IOV to zero, (iv) summing variances of interindividual variability (IIV) and IOV into a single IIV term, or (v) re‐estimating the model without IOV. The impact of varying IOV magnitudes (0–50%) and number of occasions/observations was explored. The approaches were compared with conventional weight‐based dosing. Predictive performance was assessed with the prediction error percentiles.Results: When IOV was lower than IIV, the accuracy was good for all approaches (50th percentile of the prediction error [P50] <7.4%), but the precision varied substantially between IOV magnitudes (P97.5 61–528%). Approach (ii) was the most precise forecasting method across a wide range of scenarios, particularly in case of sparse sampling or high magnitudes of IOV. Weight‐based dosing led to less precise predictions than the model‐based TDM approaches in most scenarios.Conclusions: Based on the studied scenarios and theoretical expectations, the best approach to handle IOV in model‐based dose individualization is to include IOV in the generation of the EBEs but exclude the portion of unexplained variability related to IOV in the individual parameters used to calculate the future dose.

27 July 2007 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
SFS. Fanta
S. Fanta
SJSiv Jonsson
Siv Jonsson
JBJ. T. Backman
J. T. Backman
MKM. O. Karlsson
M. O. Karlsson
KHK. Hoppu
K. Hoppu

1 September 2011 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SJSiv Jonsson
Siv Jonsson
ADAlistair Davidse
Alistair Davidse
JWJustin Wilkins
Justin Wilkins
JWJan-Stefan Van der Walt
Jan-Stefan Van der Walt
Ulrika SH SimonssonUlrika SH Simonsson
Ulrika SH Simonsson
HMHelen McIlleron
Helen McIlleron
Ethambutol, one of four drugs in the first-line antitubercular regimen, is used to protect against rifampin resistance in the event of preexisting resistance to isoniazid. The population pharmacokinetics of ethambutol in South African patients with pulmonary tuberculosis were characterized using nonlinear mixed-effects modeling. Patients from 2 centers were treated with ethambutol (800 to 1,500 mg daily) combined with standard antitubercular medication. Plasma concentrations of ethambutol were measured following multiple doses at steady state and were determined using a validated high-pressure liquid chromatography-tandem mass spectrometric method. The data comprised 189 patients (54% male, 12% HIV positive) weighing 47 kg, on average (range, 29 to 86 kg), and having a mean age of 36 years (range, 16 to 72 years). The estimated creatinine clearance was 79 ml/min (range, 23 to 150 ml/min). A two-compartment model with one transit compartment prior to first-order absorption and allometric scaling by body weight on clearance and volume terms was selected. HIV infection was associated with a 15% reduction in bioavailability. Renal function was not related to ethambutol clearance in this cohort. Interoccasion variability exceeded interindividual variability for oral clearance (coefficient of variation, 36 versus 20%). Typical oral clearance in this analysis (39.9 liters/h for a 50-kg individual) was lower than that previously reported, a finding partly explained by the differences in body weight between the studied populations. In summary, a population model describing the pharmacokinetics of ethambutol in South African tuberculosis patients was developed, but additional studies are needed to characterize the effects of renal function.